Skip to main content
    C

    Chemomab Therapeutics Ltd DRC (CMMB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.62
    +0.09 (+5.88%)

    Market Cap: $12.31M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Chemomab Therapeutics Ltd DRC (CMMB) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Chemomab Therapeutics Ltd DRC are CytoMed Therapeutics Limited Ordinary Shares (GDTC), Marker Therapeutics (MRKR) and Quantum BioPharma (QNTM). By market cap, Chemomab Therapeutics Ltd DRC ranks 6th of the 13 companies on this page; Context Therapeutics (CNTX) is the largest at $16.61M.

    Peer Comparison

    CMMB's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Chemomab Therapeutics Ltd DRC (CMMB)$12.31MN/AN/A0.0%N/A0.0%0.00%
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)$9.90MN/A16.4x0.0%-72.3%-15.9%0.00%
    Marker Therapeutics Inc (MRKR)$14.51MN/A14.5x-245.5%N/A-51.0%0.00%
    Quantum BioPharma Ltd. (QNTM)$10.35MN/AN/A0.0%-150.1%0.0%0.00%
    Moleculin Biotech Inc (MBRX)$8.02MN/AN/A0.0%N/A0.0%0.00%
    Vyome Holdings, Inc. (HIND)$11.09MN/AN/A0.0%N/A67.5%0.00%
    Tempest Therapeutics Inc (TPST)$7.64MN/AN/A0.0%-783.6%0.0%0.00%
    Akari Therapeutics PLC (AKTX)$15.54MN/AN/A0.0%N/A0.0%0.00%
    Context Therapeutics Inc (CNTX)$16.61MN/AN/A0.0%N/A0.0%0.00%
    Fractyl Health, Inc. Common Stock (GUTS)$11.99MN/AN/A0.0%-245.8%-57.1%0.00%
    FibroBiologics, Inc. Common Stock (FBLG)$6.57MN/AN/A0.0%N/A0.0%0.00%
    Biocardia Inc (BCDA)$12.58MN/AN/A0.0%N/A-100.0%0.00%
    Collplant Biotechnologies Ltd (CLGN)$14.27MN/A21.0x0.0%N/A-39.7%0.00%
    Peer median$11.54MN/A16.4x0.0%-197.9%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Chemomab Therapeutics Ltd DRC, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)
    CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human...
    Marker Therapeutics Inc (MRKR)
    Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based...
    MRKR competitors
    Quantum BioPharma Ltd. (QNTM)
    Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases.
    QNTM competitors
    Moleculin Biotech Inc (MBRX)
    Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant...
    MBRX competitors
    Vyome Holdings, Inc. (HIND)
    Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States...
    HIND competitors
    Tempest Therapeutics Inc (TPST)
    Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated...
    TPST competitors
    Akari Therapeutics PLC (AKTX)
    Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory...
    AKTX competitors
    Context Therapeutics Inc (CNTX)
    Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid...
    CNTX competitors
    Fractyl Health, Inc. Common Stock (GUTS)
    Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
    GUTS competitors
    FibroBiologics, Inc. Common Stock (FBLG)
    FibroBiologics, Inc. is an innovative biotechnology company dedicated to advancing regenerative medicine through its proprietary fibroblast cell technology...
    FBLG competitors
    Biocardia Inc (BCDA)
    BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease.
    BCDA competitors
    Collplant Biotechnologies Ltd (CLGN)
    CollPlant Biotechnologies Ltd., an aesthetic and regenerative medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs...
    CLGN competitors

    Frequently Asked Questions About CMMB

    Who are Chemomab Therapeutics Ltd DRC's main competitors?

    The companies most similar to Chemomab Therapeutics Ltd DRC include CytoMed Therapeutics Limited Ordinary Shares (GDTC), Marker Therapeutics (MRKR), Quantum BioPharma (QNTM), Moleculin Biotech (MBRX) and Vyome Holdings (HIND), listed from the closest match.

    Who is Chemomab Therapeutics Ltd DRC's biggest competitor?

    Context Therapeutics (CNTX) is the largest of the similar companies at $16.61M; CytoMed Therapeutics Limited Ordinary Shares (GDTC) is the closest match by business profile, size, sector and industry.

    How does CMMB stock compare with its competitors?

    CMMB's net margin is 0.0% against a peer median of 0.0%.

    Which of Chemomab Therapeutics Ltd DRC's competitors pays a higher dividend?

    Chemomab Therapeutics Ltd DRC pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Chemomab Therapeutics Ltd DRC bigger than its competitors?

    No. Chemomab Therapeutics Ltd DRC is 6th by market cap among the 13 companies on this page; the largest is Context Therapeutics (CNTX) at $16.61M.